FDC Ltd

Regulatory approval

• FDC International Limited has received MHRA marketing authorisation for Atropine 1.0% Eye Drops in the UK.

Dematerialisation status

• Requests processed; confirmations sent to depositories.
• Securities dematerialised have been listed on exchanges where existing securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled after verification; depository name substituted in records.

Q4 and FY26 results

• FDC reported Q4 FY26 revenue of Rs. 585 crore, up 18.9% year-on-year.
• FY26 revenue rose 3.0% to Rs. 2,171 crore.
• Q4 FY26 EBITDA increased 97.0% to Rs. 106 crore.
• Q4 EBITDA margin expanded to 18.2% from 11.0%.
• FY26 EBITDA rose 6.6% to Rs. 346 crore, with 15.9% margin.
• Q4 PAT jumped 167.4% to Rs. 103 crore.
• FY26 PAT increased 5.5% to Rs. 281 crore.

Business performance

• Domestic formulations revenue grew 8.5% in Q4 to Rs. 452 crore.
• Domestic formulations FY26 sales were flat at Rs. 1,781 crore.
• Export formulations revenue rose 99.3% in Q4 to Rs. 89 crore.
• Export formulations FY26 sales increased 23.5% to Rs. 260 crore.
• API revenue grew 38.6% in Q4 to Rs. 42 crore.
• API FY26 sales increased 8.5% to Rs. 121 crore.

US business and approvals

• US business revenue grew 46.9% year-on-year in Q4.
• Q4 US supplies rose 165.1% to Rs. 71 crore.
• Improved execution and partner profit share supported US performance.
• FDC received US FDA approval for Fluconazole Tablets USP 50mg, 100mg, 150mg and 200mg.

Operational commentary

• Management said higher gross margins and operational efficiencies drove profitability improvement.
• Domestic growth was muted for FY26 due to weaker performance in Zifi, Electral and Enerzal.

Meeting Details

• Board meeting scheduled for May 27, 2026.
• Meeting location: FDC House, C-11&12, Dalia Industrial Estate, Oshiwara Village, Andheri West, Mumbai 400053.

Key Agenda Items

• Approve audited standalone and consolidated financial results for quarter and year ended March 31, 2026.

Other Notes

• Trading window closed from April 1, 2026 until 48 hours after results declaration.